GILD Gilead Sciences
- 67.800
- +0.510+0.76%
Gilead Sciences News
Gilead Sciences (GILD) Gets a Hold From Wells Fargo
Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024
Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research to be presented at the European Association for the Study of the Liver (EASL) Congress, June 5-8, 2024 in Milan, Italy. Key findings from more than 25 abstracts will include:
$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 3.07% on an annualized basis producing an average annual return of 11.12%. Currently, Gilead Sciences has a market c
Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
Saturday, Gilead Sciences Inc (NASDAQ:GILD), following the recent acquisition of CymaBay Therapeutics Inc, announced interim results from the ongoing ASSURE study.The ASSURE study is an open-label stu
Express News | Reported Saturday, Gilead Sciences Announced That The Investigational Seladelpar Shows Significant Improvements In Liver Disease Progression And Itch Reduction In Primary Biliary Cholangitis
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC).
Gilead (GILD.US) /ArcellX's Next-Generation BCMA CAR-T Launches Phase III Clinical Trial
Gilead (GILD.US) and ArcellX registered a phase III clinical trial of Anitocabtagene Autoleucel for the treatment of recurrent or refractory multiple myeloma on the ClinicalTrials.gov website.
Market Whales and Their Recent Bets on GILD Options
Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead Sciences (NASDAQ:GILD) revealed 13 unusual trades.Delving into the details, we foun
Gilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference (Transcript)
Gilead Sciences, Inc. (GILD) BofA Securities 2024 Health Care Conference (Transcript)
Gilead Sciences Stock Outlook: Is Wall Street Bullish or Bearish?
Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care
NORTHAMPTON, MA / ACCESSWIRE / May 14, 2024 / Olivia Sloan was pursuing a career in health policy and research when her father was diagnosed with non-Hodgkin lymphoma. The devastating news put her wor
One Stock Is Dragging Down the S&P 500's Earnings Growth
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
The Jackson Laboratory and AbTherx Announce Partnership to Enhance Therapeutic Antibody Discovery
BAR HARBOR, Maine and MOUNTAIN VIEW, Calif., May 10, 2024 /PRNewswire/ -- The Jackson Laboratory (JAX), an independent, nonprofit biomedical research organization, and AbTherx, an innovator in biotec
Decoding Gilead Sciences's Options Activity: What's the Big Picture?
Financial giants have made a conspicuous bullish move on Gilead Sciences. Our analysis of options history for Gilead Sciences (NASDAQ:GILD) revealed 9 unusual trades.Delving into the details, we found
Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Gilead's Kite, Arcellx Share Phase 3 Trial Design for CAR-T Multiple Myeloma Asset
Express News | Arcellx Inc - Kite Expects Immagine-3 Trial to Start in Second Half of 2024
Express News | Arcellx Inc - Co, Kite Share Design of Global Phase 3 Trial, Immagine-3
Express News | Arcellx Inc - Remain on Track to Present Preliminary Data From Immagine-1 Trial by End of Year
Analysis
Price Target
No Data
